Neumora Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021
Market Capitalization	1,563	2,604	-	-
Enterprise Value	1,144	2,154	-365	-407
PE Ratio	-	-11.04	-	-
PB Ratio	3.68	5.55	-	-
P/FCF Ratio	-	-15.93	-	-
P/OCF Ratio	-	-15.95	-	-
EV/EBITDA Ratio	-	-9.30	2.84	1.73
EV/EBIT Ratio	-	-9.14	2.79	1.72
EV/FCF Ratio	-	-13.18	3.16	5.34
Debt / Equity Ratio	0.01	0.01	-0.02	-0.01
Debt / EBITDA Ratio	-	-0.02	-0.07	-0.01
Debt / FCF Ratio	-	-0.03	-0.07	-0.03
Quick Ratio	17.23	18.13	15.75	17.59
Current Ratio	17.99	19.05	16.37	17.85
Return on Equity (ROE)	-	-2123.00%	33.90%	-
Return on Assets (ROA)	-	-51.20%	-30.60%	-
Return on Capital (ROIC)	-	-53.15%	30.99%	73.44%
Earnings Yield	-16.25%	-9.06%	-	-
FCF Yield	-6.28%	-	-
Buyback Yield / Dilution	-439.48%	-138.99%	84.16%	-
Total Shareholder Return	-439.48%	-138.99%	84.16%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).